Agilent Technologies, Inc.
A Healthcare Medical - Diagnostics & Research NYSE
$145.49
$-2.83 (-1.91%)
Open: $148.52 | High: $149.00 | Low: $144.76 | Prev Close: $148.32
Market Cap: $41.25B
Volume: 2.0M | Avg: 1.8M
Last updated: December 05, 2025 at 10:00 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 525
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 31.84 |
| P/B Ratio | 6.11 |
| P/S Ratio | 5.94 |
| EPS | $4.57 |
| Beta | 1.27 |
| Shares Outstanding | 283.50M |
| 52-Week High | $160.27 |
| 52-Week Low | $96.43 |
| SMA 50 | $143.71 |
| SMA 200 | $123.87 |
| Dividend Yield | 0.68% |
| Annual Dividend | $0.99 |
| Next Earnings | February 25, 2026 05:00 AM ET |
Financial Ratios
| Gross Margin | 52.4% |
| Operating Margin | 21.3% |
| Net Margin | 18.8% |
| ROE | 20.6% |
| ROA | 10.2% |
| Debt/Equity | 0.50 |
| Current Ratio | 1.96 |
| Quick Ratio | 1.52 |
Balance Sheet
| Total Assets | $12.73B |
| Total Liabilities | $5.99B |
| Total Equity | $6.74B |
| Cash | $1.79B |
| Total Debt | $3.35B |
| Net Debt | $1.56B |
Income Statement
| Revenue | $6.95B |
| Gross Profit | $3.64B |
| Operating Income | $1.48B |
| Net Income | $1.30B |
| EBITDA | $1.83B |
| Revenue/Share | $24.55 |
Cash Flow
| Operating CF | $1.56B |
| CapEx | $407.00M |
| Free Cash Flow | $1.15B |
| Book Value/Share | $23.82 |
| Tangible Book/Share | $6.44 |
| Equity/Share | $23.82 |
Technical Indicators
| RSI (14) | 52.73 Neutral |
| MACD |
1.97
Signal: 2.48
|
| Volatility | 24.24% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +6.08% |
| Sharpe Ratio | 0.34 Fair |
| Volatility (Ann.) | 33.59% Moderate |
| A (1Y) | +6.08% |
| S&P 500 (1Y) | +11.86% |
| Alpha (Excess Return) | -5.78% |
Sector Comparison (Healthcare)
| Metric | A | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 31.84 | 31.19 | 63% |
| P/B Ratio | 6.11 | -0.66 | 72% |
| ROE (%) | 20.62% | 9.62% | 70% |
| Net Margin (%) | 18.75% | 9.90% | 72% |
| Stock Score | 525 | 504.0 | 58% |
| 1Y Return (%) | +6.08% | +4.40% | 51% |
Historical Price Analysis (Last 200 Days)
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | $145.49 | $150.00 | $151.90 | $149.56 | $143.71 | $123.87 | 52.73 | 1.97 | 24.24% | 2865181 | Weak Short | Price Below SMAs |
Candlestick Patterns
There wasn't any recognizable pattern for the A stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| A | Agilent Technologies, Inc. (A) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Neutral | seekingalpha.com | Read More |
| A | Groupe la Francaise Purchases 5,333 Shares of Agilent Technologies, Inc. $A | Neutral | defenseworld.net | Read More |
| A | 30% of the S&P 500 Is Mag 7 Tech Stocks, but This ETF Refuses to Own a Single One | Neutral | 247wallst.com | Read More |
| A | Agilent (A) International Revenue Performance Explored | Neutral | zacks.com | Read More |
| A | Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight | Neutral | businesswire.com | Read More |
Company Information
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
| CEO | Padraig McDonnell |
| Employees | 17900 |
| Country | US |
| IPO Date | 1999-11-18 |
| Exchange | NYSE |
| Website | https://www.agilent.com |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category